Peijia medical's licensing partner, jenavalve technology, inc., is expected to be acquired by edwards lifesciences

Peijia to maintain exclusive rights in greater china to commercialize jenavalve's trilogy transcatheter heart valve (thv) system suzhou, china , july 25, 2024 /prnewswire/ -- peijia medical limited (peijia, (9996.hk)), a leading chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, today commented on the expected acquisition of jenavalve technology, inc. ("jenavalve"), an exclusive technology licensing partner of peijia, by edwards lifesciences ("edwards"). on july 24, 2024, edwards announced that it had entered into an agreement to acquire jenavalve, a pioneer in the transcatheter treatment of aortic regurgitation (ar), a deadly disease that impacts a significant and growing population and is currently untreated today.
EW Ratings Summary
EW Quant Ranking